PMID- 17239039
OWN - NLM
STAT- MEDLINE
DCOM- 20070307
LR  - 20131121
IS  - 1323-1316 (Print)
IS  - 1323-1316 (Linking)
VI  - 61
IP  - 1
DP  - 2007 Feb
TI  - Glucose and lipid metabolism of long-term risperidone monotherapy in patients 
      with schizophrenia.
PG  - 54-8
AB  - Risperidone has a relatively low risk of causing obesity and diabetes mellitus 
      and is a first-line treatment for schizophrenia. The aim of the present study was 
      to investigate glucose and lipid metabolism, and feeding-control parameters in 
      schizophrenia patients treated with long-term risperidone monotherapy. Fifteen 
      patients with paranoid-type schizophrenia who had been treated with risperidone 
      and had Global Assessment of Function (GAF) scores >70 were selected and compared 
      with healthy volunteers (n = 25). Single assessments of psychotic symptoms, 
      side-effects, Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) score, 
      bodyweight, body fat percentage and blood sampling were performed. Fasting blood 
      glucose, insulin, hemoglobin A1c, homeostasis model assessment insulin resistance 
      index (HOMA-IR), total cholesterol, triglyceride, high density lipoprotein 
      (HDL)-, low density lipoprotein-cholesterol, adiponectin, prolactin and 
      feeding-control parameters (ghrelin and leptin) were analyzed. The body fat 
      percentage (P = 0.0018), body mass index (BMI) (P = 0.0150), fasting blood 
      glucose (P = 0.0358), triglyceride (P = 0.0377), leptin (P = 0.0243), total 
      ghrelin (P = 0.0067), active ghrelin (P = 0.0241) and prolactin (P < 0.0001) 
      levels of patients treated with risperidone were significantly higher than those 
      of healthy volunteers, while the HDL-cholesterol level (P = 0.0222) was 
      significantly lower. Although the patients had very mild psychiatric symptoms and 
      maintained functionally high levels, the glucose and lipid parameters were 
      significantly impaired compared to healthy volunteers. A high level of plasma 
      ghrelin might increase appetite, leading to exacerbation of metabolic impairment.
FAU - Murashita, Mari
AU  - Murashita M
AD  - Department of Psychiatry, Hokkaido University Graduate School of Medicine, 
      Sapporo, Japan. tm-mura@jb3.so-net.ne.jp
FAU - Inoue, Takeshi
AU  - Inoue T
FAU - Kusumi, Ichiro
AU  - Kusumi I
FAU - Nakagawa, Shin
AU  - Nakagawa S
FAU - Itoh, Kouichi
AU  - Itoh K
FAU - Tanaka, Teruaki
AU  - Tanaka T
FAU - Izumi, Takeshi
AU  - Izumi T
FAU - Hosoda, Hiroshi
AU  - Hosoda H
FAU - Kangawa, Kenji
AU  - Kangawa K
FAU - Koyama, Tsukasa
AU  - Koyama T
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Psychiatry Clin Neurosci
JT  - Psychiatry and clinical neurosciences
JID - 9513551
RN  - 0 (Adiponectin)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Ghrelin)
RN  - 0 (Leptin)
RN  - 0 (Lipids)
RN  - 0 (Peptide Hormones)
RN  - IY9XDZ35W2 (Glucose)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adiponectin/blood
MH  - Adult
MH  - Antipsychotic Agents/*adverse effects/therapeutic use
MH  - Body Composition/drug effects
MH  - Body Mass Index
MH  - Cholesterol, HDL/blood
MH  - Female
MH  - Ghrelin
MH  - Glucose/*metabolism
MH  - Humans
MH  - Hypertension/drug therapy/metabolism
MH  - Leptin/blood/metabolism
MH  - Lipid Metabolism/*drug effects
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Peptide Hormones/blood/metabolism
MH  - Psychiatric Status Rating Scales
MH  - Risperidone/*adverse effects/therapeutic use
MH  - Schizophrenia/drug therapy/*metabolism
MH  - Weight Gain/drug effects
EDAT- 2007/01/24 09:00
MHDA- 2007/03/08 09:00
CRDT- 2007/01/24 09:00
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/03/08 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - PCN1610 [pii]
AID - 10.1111/j.1440-1819.2007.01610.x [doi]
PST - ppublish
SO  - Psychiatry Clin Neurosci. 2007 Feb;61(1):54-8. doi: 
      10.1111/j.1440-1819.2007.01610.x.